Research
Clinical Trials
Efficacy and tolerability of subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: a responder analysis of 2 randomized, placebo-controlled trials. Nalamachu SR, Pergolizzi J, Taylor R Jr, Slatkin NE, Barrett AC, Yu J, Bortey E, Paterson C, Forbes WP. Pain Pract 2014 May 10 [epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/24815199
A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain. Yarlas A, Miller K, Wen W, Dain B, Lynch SY, Pergolizzi JV, Raffa RB, Ripa SR. J Pain 2013 Jan;14(1):14-23.
http://www.ncbi.nlm.nih.gov/pubmed/23200931
Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Altorjay A, Melson T, Chinachoit T, Kett A, Aqua K, Levin J, Blackburn LM, Lane S, Pergolizzi JV Jr. Arch Surg 2011 Feb; 146(2):201-206.
http://www.ncbi.nlm.nih.gov/pubmed/21339433
Restoration of disk height through non-surgical spinal decompression is associated with decreased discogenic low back pain: a retrospective cohort study. Apfel CC, Cakmakkaya OS, Marin W, Richmond C, Macario A, George E, Schaefer M, Pergolizzi JV. BMC Musculoskeletal Disord 2010 Jul 8;11:155.
http://www.ncbi.nlm.nih.gov/pubmed/20615252
Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Singla NK, Singla SK, Chung F, Kutsogiannis DJ, Blackburn L, Lane SR, Levin J, Johnson B, Pergolizzi JV Jr. Anesthesiology 2010 Jul;113(1):74-82.
http://www.ncbi.nlm.nih.gov/pubmed/20526194
A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron aloen for the prevention of postoperative nausea and vomiting in the outpatient setting. Gan TJ, Sinha AC, Kovac AL, Hones RK, Cohen SA, Battikha JP, Deutsch JS, Pergolizzi JV Jr; TDS Study Group, Glass PS. Anesth Analg 2009 May;108(5):1489-1504.
http://www.ncbi.nlm.nih.gov/pubmed/19372328
A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Candiotti KA, Kovac AL, Melson TI, Clerici G, Joo Gan T, Palonsetron 04-06 Study Group. Anesth Analg 2008 Aug;107(2):445-451.
http://www.ncbi.nlm.nih.gov/pubmed/18633022
Treatment of 94 outpatients with chronic discogenic low back pain with the DRX9000: a retrospective chart review. Macario A, Richmond C, Auster M, Pergolizzi JV. Pain Pract 2008 Jan-Feb; 8(1):11-17.
http://www.ncbi.nlm.nih.gov/pubmed/18211590
Complementary and Alternative Medicine
Antioxidant and associated capacities of camu camu (Myrciaria dubia): A systematic review. Langley PC, Pergolizzi, JV Jr., Taylor R Jr., Ridgway C. J Altern Complement Med. 2014 Oct 2 [epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/25275221
Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example. Raffa RB, Pergolizzi JV Jr. J Clin Pharm Ther 2011 Jun;36(3):283-298.
http://www.ncbi.nlm.nih.gov/pubmed/21545611
Preliminary observations of a novel topical oil with analgesic properties for treatment of acute and chronic pain syndromes. Pergolizzi JV, Pappagallo M, Raffa RB, Gharibo C, Phillips RB, Desjonqueres S, Tabor A. Pain Pract 2010 May-Jun;10(3):201-213.
http://www.ncbi.nlm.nih.gov/pubmed/20230451
Geriatrics
Managing chronic pain in elderly patients requires a CHANGE of approach. Kress HG, Ahlbeck K, Aldington D, Alon E, Coaccioli S, Coluzzi F, Huygen F, Jacksch W, Kalso E, Kocot-Kepska M, Mangas AC, Margarit Ferri C, Morlion B, Muller-Schwefe G, Nicolaou A, Perez-Hernandez C, Pergolizzi J, Schafter M, Sichere P. Curr Med Res Opin 2014 June;30(6):1153-1164.
http://www.ncbi.nlm.nih.gov/pubmed/24450746
An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult. Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Nagar S, Labhsetwar S, Sinclair N, Gould EM. J Opioid Manag 2012 Nov-Dec;8(6):383-93.
http://www.ncbi.nlm.nih.gov/pubmed/23264316
Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Pergolizzi JV. Drugs Aging. 2012 Dec; 29(12):993-995.
http://www.ncbi.nlm.nih.gov/pubmed/23143940
Pain management in the elderly: an FDA Safe Use Initiative Expert Panel’s view on preventable harm associated with NSAID therapy. Taylor R J, Lemtouni S, Weiss K, Pergolizzi JV Jr. Curr Gerontol Geriatrc Res 2012;2012:196159.
http://www.ncbi.nlm.nih.gov/pubmed/22400024
Considerations on the use of oxymorphone in geriatric patients. Pergolizzi JV, Raffa RB, Gould E. Expert Opin Drug Saf 2009 Sep;8(5):603-613.
http://www.ncbi.nlm.nih.gov/pubmed/19614559
Healthcare Policy, Practices & Economics
The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. Pergolizzi JV, Jr., Ma L, Foster DR, Overholser BR, Sowinski KM, Taylor R Jr, Summers KH. J Manag Care Pharm 2014 May; 20(5):467-476.
http://www.ncbi.nlm.nih.gov/pubmed/24761818
US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. Pergolizzi JV Jr., Ben-Joseph R, Chang CL, Hess G. Curr Med Res Opin 2014 Aug;30(8):1579-1587.
http://www.ncbi.nlm.nih.gov/pubmed/24689806
Compounding pharmacies: who is in charge? Pergolizzi JV Jr, Labhsetwar S, LeQuang JA. Pain Pract 2013 Mar;13(3):253-257.
http://www.ncbi.nlm.nih.gov/pubmed/23350709
Quantifying the impact of drug-drug interactions associated with opioids. Pergolizzi JV. Am J Manag Care 2011 Sep;17 Suppl 11:S288-S292.
http://www.ncbi.nlm.nih.gov/pubmed/21999761
Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Ben-Joseph R, Ohsfeldt R, Summers KH. Pain Pract 2012 Jan;12(1):33-44.
http://www.ncbi.nlm.nih.gov/pubmed/21951824
Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pergolizzi JV Jr, Labhsetwar SA, Amy Puenpatom R, Ben-Joseph R, Ohsfeldt R, Summers KH. Pain Pract 2012 Jan;12(1):45-56.
http://www.ncbi.nlm.nih.gov/pubmed/21923882
Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph R, Summers KH. Pain Pract 2011 Jul-Aug;11(4):325-336.
http://www.ncbi.nlm.nih.gov/pubmed/21199317
The impact of pain on labor force participation, absenteeism, and presenteeism in the European Union. Langley P, Muller-Schwefe G, Nicolaou A, Liedgens H, Pergolizzi J, Varrassi G. J Med Econ 2010;13(4):662-672.
http://www.ncbi.nlm.nih.gov/pubmed/21034378
The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization, Langley P, Muller-Schwefe G, Nicolaou A, Liedgens H, Pergolizzi J, Varrassi G. J Med Econ 2010;13(3):571-581.
http://www.ncbi.nlm.nih.gov/pubmed/20815688
Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH. Pain Pract 2011 May-Jun;11(3):230-239.
http://www.ncbi.nlm.nih.gov/pubmed/20807350
Medical Education
Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriciulum. Morley-Forster PK, Pergolizzi JV, Taylor R JR, Axford-Gatley RA, Sellers EM. J Pain Res 2013 Dec 4;6:791-801.
http://www.ncbi.nlm.nih.gov/pubmed/24353438
New Healthcare Measures
New health care measures: emphasis on better management of postsurgical pain and postoperative nausea and vomiting. Pergolizzi JV, Pappagallo M, LeQuang J, Labhsetwar S, Taylor R. Hosp Pract (1995) 2014 Feb;42(1):65-74.
http://www.ncbi.nlm.nih.gov/pubmed/24566598
Obesity
Pain and obesity in the older adult. Taylor R, Pergolizzi JV, Raffa RB, Nalamachu S, Balestrieri PJ. Curr Pharm Des 2014;20(38):6037-6041.
http://www.ncbi.nlm.nih.gov/pubmed/24641223
Opioid Misuse and Abuse
Abuse-deterrent formulations of opioid analgesics. Pergolizzi JV Jr, LeQuang JA. Pain Pract 2014 Mar;14(3):204-206.
http://www.ncbi.nlm.nih.gov/pubmed/23919885
Sequestered naltrexone in sustained release morphine or oxycodone—a way to inhibit illicit use? Raffa RB, Taylor R Jr., Pergolizzi JV Jr. Expert Opin Drug Saf 2014 Feb;13(2):181-190.
http://www.ncbi.nlm.nih.gov/pubmed/24206269
Development of federally mandated risk evaluation and mitigation strategies (REMS) for transmucosal immediate-release fentanyl products. Pergolizzi JV, Gharibo CG, Gudin JA, Nalamachu SR. Pain Pract 2013 Apr;13(4):259-263.
http://www.ncbi.nlm.nih.gov/pubmed/23464790
Designing opioids that deter abuse. Raffa RB, Pergolizzi JV Jr, Muniz E, Taylor R Jr, Pergolizzi J. Pain Res Treat 2012; 2012:282981.
http://www.ncbi.nlm.nih.gov/pubmed/23213510
Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse-deterrent formulations. Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R. Curr Pharm Des 2012;18(37):6109-6115.
http://www.ncbi.nlm.nih.gov/pubmed/22747546
Dynamic risk factors in the misuse of opioid analgesics. Pergolizzi JV Jr, Gharibo C, Passik S, Labhsetwar S, Taylor R Jr, Pergolizzi JS, Muller-Schwefe G. J Psychosom Res 2012 Jun;72(6):443-451.
http://www.ncbi.nlm.nih.gov/pubmed/22656441
Naltrexone extended-release injection: an option for the management of opioid abuse. Taylor R Jr, Raffa RB, Pergolizzi JV Jr. Subst Abuse Rehabil 2011 Dec 6;2:219-226.
http://www.ncbi.nlm.nih.gov/pubmed/24474859
Opioid formulations designed to resist/deter abuse. Raffa RB, Pergolizz JV Jr. Drugs 2010 Sept 10;70(13):1657-1675l.
http://www.ncbi.nlm.nih.gov/pubmed/20731474
Pain
Treating acute pain in light of the chronification of pain. Pergolizzi JV Jr, Raffa RB, Taylor R Jr. Pain Manag Nurs. 2014 Mar;15(1):380-390.
http://www.ncbi.nlm.nih.gov/pubmed/24602441
Acute pain: effective management requires comprehensive assessment. Radnovich R, Chapman CR, Gudin JA, Panchal SJ, Webster LR, Pergolizzi JV Jr. Postgrad Med 2014 July; 126(4):59-172.
http://www.ncbi.nlm.nih.gov/pubmed/25141244
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Pergolizzi JV Jr, Taylor R Jr, Nalamachu S, Raffa RB, Carlson DR, Varanasi RK, Kopecky EA. Curr Med Res Opin 2014 Feb;30(2):191-202.
http://www.ncbi.nlm.nih.gov/pubmed/24117419
Opioid-induced hyperalgesia: is it clinically relevant for the treatment of pain patients? Raffa RB, Pergolizzi JV Jr. Pain Manag Nurs 2013 Sep; 14(3):e67-e83.
http://www.ncbi.nlm.nih.gov/pubmed/23972873
The development of chronic pain: physiologic CHANGE necessitates a multidisciplinary approach to treatment. Pergolizzi J, Ahlbeck K, Aldington D, Alon E, Coluzzi F, Dahan A, Huygen F, Kocot-Kepska M, Mangas AC, Mavrocordatos P, Morlion B, Muller-Schwefe G, Nicolaou A, Perez Hernandez C, Sicher P, Schafer M, Varrassi G. Curr Med Res Opin 2013 Sept;29(9):1127-1135.
http://www.ncbi.nlm.nih.gov/pubmed/23786498
Low back pain in a natural disaster. Angeletti C, Guetti C, Ursini ML, Taylor R Jr, Papola R, Petrucci E, Ciccozzi A, Paladini A, Marinangeli F, Pergolizzi J, Varrassi G. Pain Pract 2014 Feb;14(2):E8-E16.
http://www.ncbi.nlm.nih.gov/pubmed/23763663
Pain after earthquake. Angeletti C, Guetti C, Papola R, Petrucci E, Ursini ML, Ciccozzi A, Masi F, Russo MR, Squarcione S, Paladini A, Pergolizzi J, Taylor R Jr, Varrassi G, Marinangeli F. Scand J Trauma Resusc Emerg Med 2012 Jun 20;20:43.
http://www.ncbi.nlm.nih.gov/pubmed/22747796
The chronic pain conundrum: should we CHANGE from relying on past history to assessing prognostic factors? Pergolizzi J, J, Ahlbeck K, Aldington D, Alon E, Collett B, Coluzzi F, Huygen F, Jaksch W, Kocot-Kepska M, Mangas AC, Margarit C, Mavrocordatos P, Morlion B, Muller-Schwefe G, Nicolaou A, Perez Hernandez C, Sicher P, Varrassi G. Curr Med Res Opin 2012 Feb;28(2):249-256.
http://www.ncbi.nlm.nih.gov/pubmed/22181344
Chronic pain—moving from symptom control to mechanism-based treatment. Pergolizzi J. Curr Med Res Opin 2011 Oct;27(10):2079-2080.
http://www.ncbi.nlm.nih.gov/pubmed/21929443
Make a CHANGE: optimizing communication and pain management decisions. Muller-Schwefe G, Jaksch W, Morlion B, Kalso E, Schafer M, Coluzzi F, Huygen F, Kocot-Kepska M, Mangas AC, Margarit C, Ahlbeck K, Mavrocordatos P, Alon E, Collett B, Aldington D, Nicolaou A, Pergolizzi J, Varrassi G. Curr Med Res Opin 2011 Feb;27(2):481-488.
http://www.ncbi.nlm.nih.gov/pubmed/21194393
The emerging role of cannabinoid neuromodulators in symptom management. Davis M, Maida V, Daeninck P, Pergolizzi J. Support Care Cancer 2007 Jan;15(1):63-71.
http://www.ncbi.nlm.nih.gov/pubmed/17139494
Pharmacological Therapies
Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J Jr. Pain Med 2014 Sept 12 [epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/25220043
Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pergolizzi JV Jr, Taylor R, Raffa RB. Pain Pract 2014 Aug 28 [epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/25169467
Combining opioid and adrenergic mechanisms for chronic pain. Smith HS, Raffa RB, Pergolizzi JV, Taylor R, Tallarida RJ. Postgrad Med 2014 July; 126(4):98-114.
http://www.ncbi.nlm.nih.gov/pubmed/25141248
Opioid formulations with sequestered naltrexone: a perspective review. Taylor R, Raffa RB, Pergolizzi JV. Ther Adv Drug Saf 2014 Jun;5(3):129-37.
http://www.ncbi.nlm.nih.gov/pubmed/25083268
The clinical analgesic efficacy of buprenorphine. Raffa RB, Haidery M, Huang HM, Kalladeen K, Lockstein DE, Ono H, Shope MJ, Sowunmi OA, Tran JK, Pergolizzi JV Jr. J Clin Pharm Ther 2014 Dec; 39(6):577-583.
http://www.ncbi.nlm.nih.gov/pubmed/25070601
‘Selective’ COX-1 or COX-2 NSAIDs: Time to change a misleading measure. Raffa RB, Gudin JA, Nalamachu S, Pergolizzi JV, Jr. J Clin Pharm Ther 2014 Oct;39(5):455-456.
http://www.ncbi.nlm.nih.gov/pubmed/25070498
Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: results of in vitro laboratory analyses. Galia E, William Y, Van Hove B, Pergolizzi J, Etropolski M, Vorsander G. J Opioid Manag 2014 May-Jun;10(3):149-158.
http://www.ncbi.nlm.nih.gov/pubmed/24944065
Drug-drug interaction between NSAIDs and low-dose aspirin: a focus on cardiovascular and GI toxicity. Nalamachu S, Pergolizzi JV, Raffa RB, Lakkireddy DR, Taylor R Jr. Expert Opin Drug Saf 2014 Jul;13(7):903-917.
http://www.ncbi.nlm.nih.gov/pubmed/24905189
Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements. Müller-Schwefe G1, Ahlbeck K, Aldington D, Alon E, Coaccioli S, Coluzzi F, Huygen F, Jaksch W, Kalso E, Kocot-Kępska M, Kress HG, Mangas AC, Ferri CM, Morlion B, Nicolaou A, Hernández CP, Pergolizzi J, Schäfer M, Sichère P. Curr Med Res Opin 2014 Sep;30(9):1895-1908.
http://www.ncbi.nlm.nih.gov/pubmed/24841174
Ketorolac tromethamine-routes and clinical implications. Vadivelu N, Gowda AM, Urman RD, Jolly S, Kodumudi V, Maria M, Taylor R Jr., Pergolizzi JV Jr. Pain Pract 2014 Apr 16 [epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/24738596
Fast-acting sublingual zolpidem for middle-of-the-night wakefulness. Pergolizzi JV JR, Taylor R Jr, Raffa RB, Nalamachu S, Chopra M. Sleep Disord 2014;2014:527109 [epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/24649369
Predicting medication persistence to buprenorphine transdermal system. Pergolizz JV, Ben-Joseph R, Chang CL, Hess G. Pain Pract 2014 Jan 20 [epub ahead of print].
http://www.ncbi.nlm.nih.gov/pubmed/24444055
The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability, and health. Miller K, Yarlas A, Wen W, Dain B, Lynch SY, Ripa SR, Pergolizz JV Jr., Raffa R. Clin J Pain 2014 Dec;30(12):1015-1022.
http://www.ncbi.nlm.nih.gov/pubmed/24394747
A modern analgesic pain ‘pyramid.’ Raffa RB, Pergolizz JV Jr. J Clin Pharm Ther 2014 Feb;39(1):4-6.
http://www.ncbi.nlm.nih.gov/pubmed/24383938
Opioid antagonists for pain. Taylor R Jr, Pergolizzi JV Jr, POrreca F, Raffa RB. Expert Opin Investig Drugs 2013 Apr;22(4):517-525.
http://www.ncbi.nlm.nih.gov/pubmed/23484859
Intravenous acetaminophen reduces postoperative nausea and vomiting: a systematic review and meta-analysis. Apfel CC, Turan A, Souza K, Pergolizzi J, Ornuss C. Pain 2013 May;154(5):677-689.
http://www.ncbi.nlm.nih.gov/pubmed/23433945
Tapentadol extended release for chronic pain patients. Taylor R, Pergolizzi JV, Raffa RB. Adv Ther 2013 Jan;30(1):14-27.
http://www.ncbi.nlm.nih.gov/pubmed/23328938
Tramadol/paracetamol fixed-dose combination for chronic pain management in family practice: a clinical review. Moron Merchante I, Pergolizzi JV Jr, van de Laar M, Mellinghoff HU, Nalamachu S, O’Brien J, Perrot S, Raffa RB. ISRN Family Med 2013 Apr 11;2013:638469.
http://www.ncbi.nlm.nih.gov/pubmed/24959571
Pain treatment in arthritis-related pain: beyond NSAIDs. Van Laar M, Pergolizzi JV Jr, Mellinghoff HU, Merchante IM, Nalamachu S, O’Brien J, Perrot S, Raffa RB. Open Rheumatol J. 2012;6:320-330.
http://www.ncbi.nlm.nih.gov/pubmed/23264838
Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. Pergolizzi JV Jr, van de Laar M, Langford R, Mellinghoff HU, Merchante IM, Nalamachu S, O’Brien J, Perrot S, Raffa RB. J Pain Res 2012;5:327-346.
http://www.ncbi.nlm.nih.gov/pubmed/23055775
Transversus abdominis block: clinical uses, side effects, and future perspectives. Taylor R Jr, Pergolizzi JV, Sinclair A, Raffa RB, Aldington D, Plavin S, Apfel CC. Pain Pract 2013 Apr;13(4):332-344.
http://www.ncbi.nlm.nih.gov/pubmed/22967210
Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Daith J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J Jr. Pain Physicians 2012 Jul;15(3 Suppl):ES59-ES66.
http://www.ncbi.nlm.nih.gov/pubmed/22786462
Is morphine medicine’s biggest misnomer? Raffa RB, Pergolizzi JV Jr. Ann Pharmacother 2012 Jul-Aug;46(7-8):1122-1123.
http://www.ncbi.nlm.nih.gov/pubmed/22764325
A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletan pain due to chronic osteoarthritis pain and low back pain. Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Rodriguez G, Nalamachu S, Langley P. Pain Pract 2013 Mar;13(3):239-252.
http://www.ncbi.nlm.nih.gov/pubmed/22716295
Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature. Taylor R Jr, Raffa RB, Pergolizzi JV Jr. J Pain Res 2012;5:77-87.
http://www.ncbi.nlm.nih.gov/pubmed/22570559
QTc interval prolongation by d-propoxyphene: what about other analgesics? Raffa RB, Burmeister JJ, Yuvasheva E, Pergolizzi JV Jr. Expert Opin Pharmacother 2012 Jul;13(10):1397-1409.
http://www.ncbi.nlm.nih.gov/pubmed/22568597
Fixed-dose combinations for emerging treatment of pain. Raffa RB, Tallarida RJ, Taylor R Jr, Pergolizzi JV Jr. Expert Opin Pharmacother 2012 Jun;13(9):1261-1270.
http://www.ncbi.nlm.nih.gov/pubmed/22420908
Intracerebroventricular opioids for intractable pain. Raffa RB, Pergolizzi JV Jr. Br J Clin Pharmacol 2012 Jul;74(1):34-41.
http://www.ncbi.nlm.nih.gov/pubmed/22295988
Tapentadol in the management of chronic low back pain: a novel approach to a complex condition? Pergolizzi J, Alon E, Baron R, Bonezzi C, Dobrogowski J, Galvez R, Jensen T, Kress HG, Marcus MA, Morlion B, Perrot S, Treede RD. J Pain Res 2011;4:203-210.
http://www.ncbi.nlm.nih.gov/pubmed/21887117
Current considerations for the treatment of severe chronic pain: the potential for tapentadol. Pergolizzi J, Alegre C, Blake D, Alén JC, Caporali R, Casser HR, Correa-Illanes G, Fernandes P, Galilea E, Jany R, Jones A, Mejjad O, Morovic-Vergles J, Oteo-Álvaro Á, Radrigán Araya FJ, Simões ME, Uomo G. Pain Pract 2012 Apr;12(4):290-306.
http://www.ncbi.nlm.nih.gov/pubmed/21797962
Continuous multimechanistic postoperative analgesia: a rationale for transitioning from intravenous acetaminophen and opioids to oral formulations. Pergolzzi JV Jr, Raffa RB, Tallarida R, Taylor R, Labhsetwar SA. Pain Pract 2012 Feb;12(2):159-173.
http://www.ncbi.nlm.nih.gov/pubmed/21676161
Extended-release formulations of tramadol in the treatment of chronic pain. Pergolizzi JV Jr, Taylor R Jr, Raffa RB. Expert Opin Pharmacother 2011 Aug;12(11):1757-1768.
http://www.ncbi.nlm.nih.gov/pubmed/21609187
Multi-mechanistic analgesia for opioid-induced hyperalgesia. Raffa RB, Pergolizzi JV Jr. J Clin Pharm Ther 2012 Apr;37(2):125-127.
http://www.ncbi.nlm.nih.gov/pubmed/21501205
The evolving understanding of the analgesic mechanism of action of flupirtine. Raffa RB, Pergolizzi JV Jr. J Clin Pharm Ther 2012 Feb;37(1):4-6.
http://www.ncbi.nlm.nih.gov/pubmed/21114508
Oxycodone combinations for pain relief. Raffa RB, Pergolizzi JV, Segarnick DJ, Tallarida RJ. Drugs Today (Barc) 2010 Jun;46(6):379-398.
http://www.ncbi.nlm.nih.gov/pubmed/20571607
Current knowledge of buprenorphine and its unique pharmacological profile. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, Mercadante S, Morlion B, Raffa RB, Sabatowski R, Sacerdote P, Torres LM, Weinbroum AA. Pain Pract 2010 Sept-Oct;10(5):428-450.
http://www.ncbi.nlm.nih.gov/pubmed/20492579
Cohort study finds nine times increased overdose risk (fatal plus non-fatal) in patients receiving 100 mg/day for 90 days compared with 1-20 mg/day opioids for chronic non-cancer pain, but wide CI and possibility of unmeasured confounders. Hochman JS, Pergolizzi J. Evid Based Nurs 2010 Apr;13(2):55-56.
http://www.ncbi.nlm.nih.gov/pubmed/20436154
The determination and application of fixed-dose analgesic combinations for treating multimodal pain. Raffa RB, Pergolizzi JV Jr, Tallarida RJ. J Pain 2010 Aug;11(8):701-709.
http://www.ncbi.nlm.nih.gov/pubmed/20338825
Pharmacological treatment of chronic pain—the need for CHANGE. Varrassi G, Muller-Schwefe G, Pergolizzi J, Oronska A, Morlion B, Mavrocordatos P, Margarit C, Mangas C, Jacksch W, Huygen F, Collett B, Berti M, Aldington D, Ahlbeck K. Curr Med Res Opin 2010 May;26(5):1231-1245.
http://www.ncbi.nlm.nih.gov/pubmed/20337502
Postoperative Nausea and/or Vomiting
The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting. Antor MA, Uribe AA, Erminy-Falcon N, Werner JG, Candiotti KA, Pergolizzi JV, Bergese SD. Front Pharmacol 2014 Apr 9;5:55.
http://www.ncbi.nlm.nih.gov/pubmed/24782768
Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. Pergolizzi JV Jr, Philip BK, Leslie JB, Taylor R Jr, Raffa RB. J Clin Anesth 2012 Jun;24(4):334-345.
http://www.ncbi.nlm.nih.gov/pubmed/22608591
Prophylaxis of postoperative nausea and vomiting in adolescent patients: a review with emphasis on combination of fixed-dose ondansetron and transdermal scopolamine. Pergolizzi JV, Raffa R, Taylor R. J Drug Delv 2011;2011:426813.
http://www.ncbi.nlm.nih.gov/pubmed/21773046
Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Apfel CC, Zhang K, George E, Shi S, Jalota L, Hornuss C, Fero KE, Heidrich F, Pergolizzi JV, Cakmakkaya OS, Kranke P. Clin Ther 2010 Nov;32(12):1987-2002.
http://www.ncbi.nlm.nih.gov/pubmed/21118734
Anesthesiologists’ practice patterns for treatment of postoperative nausea and vomiting in the ambulatory Post Anesthesia Care Unit. Marcario A, Claybon L, Pergolizzi JV. BMC Anesthesiol 2006 Jun 1;6:6.
http://www.ncbi.nlm.nih.gov/pubmed/16740165
Proceedings from Meetings and Conferences and Expert Panels
Proceedings of the CHANGE PAIN Expert Summit in Rome, June 2010. Varrassi G, Collett B, Morlion B, Kalso E, Nicolaou A, Dickenson A, Pergolizzi J, Schafrer M, Muller-Schwefe G. Curr Med Res Opin 2011 Oct;27(10):2061-2062.
http://www.ncbi.nlm.nih.gov/pubmed/21929436
The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Pergolizzi JV Jr, Mercadante S, Echaburu AV, Van de Eynden B, Fragoso RM, Mordarski S, Lybaert W, Beniak J, Oronska A, Slama O, Euromed Communications Meeting. Curr Med Res Opin 2009 Jun;25(6):1517-1528.
http://www.ncbi.nlm.nih.gov/pubmed/19435402
Opioids and the management of chronic severe pain in the elderly; consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Pain Pract 2008 Jul-Aug;8(4):287-313.
http://www.ncbi.nlm.nih.gov/pubmed/18503626
Spinal Decompression
Systematic literature review of spinal decompression via motorized traction for chronic discogenic low back pain. Marcario A, Pergolizzi JV. Pain Pract 2006 Sep;6(3):171-178.
http://www.ncbi.nlm.nih.gov/pubmed/17147594
Surgery and Surgery-Related Topics
Regional anaesthesia techniques for carotid surgery: the state of the art. Ciccozzi A, Angeletti C, Guetti C, Pergolizzi J, Angeletti PM, Mariani R, Marinangeli F. J Ultrasound 2014 May 1 [epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/25177390
Anesthetic routines: the anesthesiologist’s role in GI recovery and postoperative ileus. Leslie JB, Viscusi ER, Pergolizzi JV Jr, Panchal SJ. Adv Prev Med 2011; 2011:976904.
http://www.ncbi.nlm.nih.gov/pubmed/21991449
Perspectives on the role of fospropofol in the monitored anesthesia care setting. Pergolizzi JV Jr, Gan TJ, Plavin S, Labhsetwar S, Taylor R. Anesthesiol Res Pract 2011;2011:458920.
http://www.ncbi.nlm.nih.gov/pubmed/21541247
Survey Studies
Bullying in middle school: results from a 2008 survey. Pergolizzi F, Pergolizzi J 3rd, Gan Z, Macario S, Pergolizzi JV Jr, Ewin TJ, Gan TJ. Int J Adolesc Med Health 2011;23(1):11-18.
http://www.ncbi.nlm.nih.gov/pubmed/21721358
The role of urine drug testing for patients on opioid therapy. Pergolizzi J, Pappagallo M, Stauffer J, Gharibo C, Fortner N, De Jesus MN, Brennan MJ, Richmond C, Hussey D; Integrated Drug Compliance Study Group (IDCSG). Pain Pract 2010 Nov-Dec;10(6):497-507.